Elanco Animal Health Reports the USDA Approval of Befrena (Tirnovetmab) for Canine Allergic and Atopic Dermatitis

Shots: The USDA has granted Befrena (Tirnovetmab) for Canine Allergic and Atopic Dermatitis, expected to launch in H1’26 Befrena (mAb) is an anti-IL31 injection for dogs, treats allergic and atopic dermatitis every 6–8 wks. In September, the FDA approved changes to Zenrelia (ilunocitinib tablets) US label, eliminating the fatal vaccine-induced disease risk, Elanco announced Ref:…

ByDipanshu DixitJanuary 1, 2026

Vivani Medical & Okava Pharmaceuticals Extend Collaboration to Develop OKV-119 for Canine Cardiometabolic Diseases

Shots: Vivani Medical & Okava Pharmaceuticals have expanded their 2019 collaboration to develop OKV-119 for cardiometabolic conditions in dogs, which initially focused on cats Financial terms of the expanded agreement remain undisclosed but incl. future milestones & royalty payments to Vivani OKV-119 (GLP-1 receptor agonists) uses Vivani’s NanoPortal tech for steady drug delivery over time from…

ByRidhi RastogiApril 16, 2025

GumPaws Launches Gummy Supplements to Promote Dental Health in Dogs

Shots: GumPaws has launched gummy supplements to support dental health in dogs GumPaws gummies are designed with specific density & chewiness to improve friction, helping clean plaque & support dental care in dogs, offering dual-benefit compared to conventional supplements Gummies are formulated with scientifically-backed natural ingredients that start absorbing through the gums &…

ByRidhi RastogiMarch 7, 2025

Elanco Animal Health Reports the USDA Approval of Befrena (Tirnovetmab) for Canine Allergic and Atopic Dermatitis

Vivani Medical & Okava Pharmaceuticals Extend Collaboration to Develop OKV-119 for Canine Cardiometabolic Diseases

GumPaws Launches Gummy Supplements to Promote Dental Health in Dogs

Contact US

FOLLOW US